A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Inclusion Criteria: * 18 years of age or older * KRAS/NRAS/BRAF wild type colorectal cancer, not responsive to standard therapies, no approved or curative therapy, refuse standard therapy * Prior 5-FU, oxaliplatin and irinotecan * ECOG Performance Status of 0 or 1 * Able to swallow/retain oral drugs * Able and agree to have provide tumor tissue/have biopsies * Agree to use contraception * Not pregnant * Adequate organ system function Exclusion Criteria: * Chemotherapy, radiotherapy, immunotherapy, or other anti-cancer therapies \<28 days or 5 half lives * Prior EGFR, MEK, or RAF inhibitor or regorafenib * Current use of prohibited medications * Unresolved side effects * GI disease or other condition affecting GI absorption * Mucosal or internal bleeding * Any major surgery \<four weeks * HIV, HBV, or HCV positive * Active infection * Leptomeningeal disease * Brain metastases * Unacceptable QTcF interval * Significant uncontrolled arrhythmias * Acute coronary syndromes, myocardial infarction, coronary angioplasty, or stenting or bypass grafting \< 6 mos. * Class II, III, or IV heart failure * Other clinically significant ECGs * Intra - cardiac defibrillators * Cardiac metastases * Condition that may interfere with patient safety * Hypersensitivity to study drugs * Severe or uncontrolled systemic diseases * Pregnant or lactating * Retinal vein occlusion * Interstitial lung disease or pneumonitis * Active liver or biliary disease